Brought to you by 
MedImmune and WuXi AppTec form JV to develop MedImmune's MEDI5117
19 Jan 2023
Executive Summary
AstraZeneca PLC’s MedImmune LLC is taking advantage of an opportunity to develop and sell one of its compounds in China by creating a 50/50 joint venture with WuXi AppTec Inc. (biopharma and device R&D outsourcing). The JV will be tasked with turning out MEDI5117, an autoimmune and inflammatory disease candidate that is currently in Phase I trials in the US and Europe.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune and WuXi AppTec form JV to develop MedImmune's MEDI5117
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice